33 studies found for:    "Merkel cell carcinoma"
Show Display Options
Rank Status Study
1 Recruiting Study of aNK (Activated NK-92, Formerly Neukoplast) Infusions in Patients With Unresectable Stage III (IIIB) or Distant Metastatic (IV) Merkel Cell Carcinoma (MCC)
Conditions: Stage IIIB Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma
Intervention: Biological: aNK
2 Recruiting Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
Conditions: Recurrent Merkel Cell Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
3 Recruiting MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Intervention: Drug: MLN0128
4 Terminated Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Conditions: Recurrent Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma
Interventions: Biological: Aldesleukin;   Other: Laboratory Biomarker Analysis;   Biological: MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells;   Radiation: Radiation Therapy;   Biological: Recombinant Interferon Beta
5 Recruiting Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Conditions: Merkel Cell Carcinoma;   Skin Cancer
Intervention: Drug: Cabozantinib
6 Active, not recruiting A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Intervention: Biological: GLA-SE
7 Recruiting Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation
Condition: Merkel Cell Carcinoma
Intervention: Drug: Ipilimumab
8 Recruiting F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Interventions: Drug: Arm A: F16IL2 in combination with paclitaxel;   Drug: Arm B: Paclitaxel
9 Completed Oblimersen in Treating Patients With Merkel Cell Carcinoma
Conditions: Recurrent Neuroendocrine Carcinoma of the Skin;   Stage I Neuroendocrine Carcinoma of the Skin;   Stage II Neuroendocrine Carcinoma of the Skin;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin
Interventions: Biological: oblimersen sodium;   Other: pharmacological study;   Other: laboratory biomarker analysis
10 Completed A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma
Condition: Metastatic Melanoma and Merkel Cell Carcinoma
Interventions: Drug: Pasireotide sub-cutaneous formulation;   Drug: Pasireotide lon acting release formulation
11 Withdrawn Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Intervention: Drug: Ipilimumab
12 Recruiting A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Conditions: Melanoma;   Merkel Cell Carcinoma;   Other Solid Tumors
Interventions: Drug: TALIMOGENE LAHERPAREPVEC (TVEC);   Radiation: Hypofractionated Radiotherapy
13 Recruiting Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
Conditions: Merkel Cell Polyomavirus Infection;   Stage IV Merkel Cell Carcinoma
Interventions: Drug: Avelumab;   Other: Laboratory Biomarker Analysis;   Biological: MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells;   Radiation: Radiation Therapy;   Biological: Recombinant Interferon Beta
14 Active, not recruiting IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer
Condition: Merkel Cell Carcinoma
Interventions: Biological: interleukin-12 gene;   Biological: electroporation-mediated plasmid DNA vaccine therapy
15 Completed S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Conditions: Recurrent Neuroendocrine Carcinoma of the Skin;   Stage II Neuroendocrine Carcinoma of the Skin;   Stage III Neuroendocrine Carcinoma of the Skin
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis
16 Recruiting Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Condition: Carcinoma, Merkel Cell
Intervention: Drug: Avelumab
17 Completed S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer
Condition: Neuroendocrine Carcinoma of the Skin
Interventions: Drug: CMF regimen;   Drug: cyclophosphamide;   Drug: fluorouracil;   Drug: methotrexate
18 Not yet recruiting Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Conditions: Functional Pancreatic Neuroendocrine Tumor;   Malignant Somatostatinoma;   Merkel Cell Carcinoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Carcinoid Tumor;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B;   Neuroendocrine Neoplasm;   Non-Functional Pancreatic Neuroendocrine Tumor;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Merkel Cell Carcinoma;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Adrenal Cortex Carcinoma;   Stage III Thyroid Gland Medullary Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IVA Thyroid Gland Medullary Carcinoma;   Stage IVB Thyroid Gland Medullary Carcinoma;   Stage IVC Thyroid Gland Medullary Carcinoma;   Thymic Carcinoid Tumor;   VIP-Producing Neuroendocrine Tumor;   Well Differentiated Adrenal Cortex Carcinoma;   Zollinger Ellison Syndrome
Interventions: Drug: Capecitabine;   Drug: Temozolomide;   Drug: Veliparib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
19 Recruiting Merkel Positron Emission Tomography (PET) Protocol
Condition: Merkel Cell Carcinoma
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Radiation: Radiotherapy
20 Completed Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Conditions: Gastrin-Producing Neuroendocrine Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Paraganglioma;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Merkel Cell Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Biological: Cixutumumab;   Drug: Everolimus;   Other: Laboratory Biomarker Analysis;   Drug: Octreotide Acetate;   Other: Pharmacological Study

   Previous Page Studies Shown (1-20) Next Page (21-33) Show next page of results    Last Page
Indicates status has not been verified in more than two years